SCL Science Inc.
KKRX:2469602,300.00
KRW
0.00
(0.00%)
ISIN
KR7246960009
Return %
Stock
S&P 500
1Y
-9.80
14.39
3Y
21.53
81.42
5Y
-32.85
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 163
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Feb 1, 2019
- Website
- sclscience.com
- Similar Companies
- Business
- SCL Science Inc. is a South Korea-based medical device, biotechnology, and digital healthcare company specializing in biomimetic surgical adhesives, precision medicine, and specialized bio-logistics services. Founded in 2010 and headquartered in Seoul, South Korea, the company operates as a key healthcare affiliate of SCL Holdings and serves hospitals, surgical centers, clinical trial institutions, and biopharmaceutical enterprises across domestic and international markets. SCL Science develops, manufactures, and commercializes proprietary biopolymer-based products and clinical support services across several primary business segments: Biomaterial Medical Devices, Specialized Bio-Logistics, and Precision Medicine and Therapeutics. The company's core product and service portfolio includes bio-inspired hemostatic agents developed with proprietary chitosan-catechol biopolymer technology, comprising InnoSEAL, a topical hemostatic pad for vascular access site closure and external bleeding management; InnoSEAL Plus and InnoSEAL Plus DL, absorbable surgical hemostat sponges engineered for rapid tissue adhesion and intraoperative bleeding control; EndoSeal, an endoscopic hemostatic formulation for gastrointestinal bleeding interventions; and GellySil, an absorbable sealant for tissue repair and surgical wound sealing. In addition, the company provides temperature-controlled cold-chain specimen transport and logistics for clinical research, biological data management solutions, and genomic clinical diagnostic support. In recent major corporate developments, the company underwent a strategic repositioning following its acquisition by SCL Holdings, officially changing its corporate name from InnoTherapy, Inc. to SCL Science Inc. in March 2024 to consolidate its role as the digital healthcare and precision medicine hub within SCL Group. Concurrently, SCL Science completed internal business integrations and expanded hospital formulary listings and clinical adoption of its flagship InnoSEAL Plus line across major medical institutions. The company has also expanded into oncology therapeutics through its biotechnology subsidiary, Neogen Logic, advancing personalized cancer vaccine research utilizing its DeepNeo platform and securing a United States patent for artificial intelligence-powered immune response prediction technology.